Thelansis

 Proteus syndrome (PS) is an exceptionally rare and intricate disorder characterized by excessive growth in the skeletal, skin, adipose tissue, and central nervous system. Causal mutations for PS have been identified in two components of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway: PTEN, linking PS to the PTEN Hamartoma Tumor Syndrome (PTHS), and AKT1. The AKT1 mutation is typically a somatic mosaic mutation, found in 1-47% of cases. Newborns with PS usually appear normal at birth. Symptoms typically manifest between 6 and 18 months of age and often involve asymmetric overgrowth, primarily in the hands or feet. Macrodactyly, characterized by abnormally large digits, is the most common initial symptom, often accompanied by hemihypertrophy. Skeletal overgrowth can progress rapidly, resulting in irregular, distorted, and calcified growth in the tubular bones of the limbs, skull, and vertebral bodies. Diagnosing PS relies on specific clinical criteria. To establish a...

  Proteus syndrome is a rare condition characterized by overgrowth of the bones, skin, and other tissues. Organs and tissues affected by the disease grow out of proportion to the rest of the body. Proteus syndrome results from a mutation in the AKT1 gene. The AKT1 gene helps regulate cell growth, division (proliferation), and death. Some reports suggested that mutations in a gene called PTEN have been associated with Proteus syndrome. Proteus syndrome is a rare condition with an incidence of less than 1 in a million people worldwide. Thelansis’s “Proteus Syndrome Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Proteus Syndrome treatment modalities options for eight major markets (USA, ...